文献速递眼底病与葡萄膜炎

渗出性年龄相关性黄斑变性患者接受雷珠单抗玻璃体内注射后换用阿柏西普:ARI2研究

AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: The ARI2 Study.
PubMed 文献 · Retina · 2018-01-01

多中心前瞻性非随机临床试验纳入84例既往接受至少6次雷珠单抗注射的渗出性年龄相关性黄斑变性伴PED高度>250μm患者,换用阿柏西普固定方案后第12周PED高度和体积显著降低,第32周BCVA提高3.3个ETDRS字母。

要点

  • 换用阿柏西普后第12周PED最大高度从基线347μm降至266μm(P<0.001)。
  • 第32周PED高度降至288.2μm(P<0.001),PED体积从1.3mm降至0.98mm(P<0.001)。
  • 第32周BCVA提高3.3个ETDRS字母(P=0.003)。

核心结论

  • 对于既往接受按需雷珠单抗治疗的患者,换用阿柏西普治疗似乎对大PED有效。

研究设计与样本

  • 多中心、前瞻性、非随机临床试验,纳入84例新生血管性年龄相关性黄斑变性伴PED高度>250μm且持续积液的患者,每例纳入一眼。

主要发现

  • 末次雷珠单抗注射至换药的平均间隔为44.7天。
  • 基线平均PED最大高度为347μm(±109),第12周降至平均266μm(±114)(P<0.001),第32周为288.2μm(P<0.001)。
  • 平均PED体积从1.3mm降至第12周0.98mm(P<0.001)。
  • BCVA在第32周提高3.3个ETDRS字母(P=0.003)。

关键数值与推荐

  • 纳入标准:PED高度>250μm且持续积液;入组前12个月内至少接受6次雷珠单抗玻璃体内注射。
  • 换药方案:从雷珠单抗按需治疗换为阿柏西普固定方案,即每月3次玻璃体内注射,然后每6周一次。
  • 主要结局指标:换药后第12周PED高度较基线的变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To analyze the efficacy of aflibercept switch treatment for regression of pigment epithelial detachment (PED) in patients previously treated with ranibizumab. METHODS: Multicenter, prospective, nonrandomized clinical trial. One eye of patients presenting neovascular age-related macular degeneration with PED of more than 250 μm in height, with persistent fluid, was included. Patients had to have received at least six ranibizumab intravitreal injections during the 12 months before enrollment. Patients were switched from ranibizumab pro re nata to aflibercept (fixed regimen, 3 monthly intravitreal injections, and then Q6). Main outcome measure was change in PED height from baseline to Week 12 after switch. Secondary outcomes were best-corrected visual acuity and PED volume changes. RESULTS: Eighty four patients were included. Mean delay between last ranibizumab intravitreal injection and switch was 44.7 days. Mean maximal PED height at baseline visit was 347 μm (±109) and reduced to a mean of 266 μm (±114) at Week 12 (P < 0.001) and 288.2 μm at Week 32 (P < 0.001). Mean PED volume was reduced from 1.3 mm to 0.98 mm at Week 12 (P < 0.001). Best-corrected visual acuity improved by 3.3 Early Treatment Diabetic Retinopathy Study letters at Week 32 (P = 0.003). CONCLUSION: Aflibercept switch therapy seems to be effective on large PED in patients previously treated with pro re nata ranibizumab.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Blanco-Garavito R, Jung C, Uzzan J, et al. AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: The ARI2 Study. Retina. 2018. PMID: 29190241. doi:10.1097/IAE.0000000000001928

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。